Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolism Study of 14C-Z-215 in Healthy Males
NCT02618629Phase 1Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azeloprazole in reflux esophagitis, sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoints: Mass balance recovery of total radioactivity concentration in plasma, red blood cells and whole blood at 240 hours, Concentration of Z-215 in plasma at 240 hours and 2 more. Started Jan 2016; status: completed.
02
Drugs
azeloprazole
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT02618629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618629.